Abbott

2Q Revenues: $9.8 billion (+2%)

2Q Earnings: $1.7 billion (-11%)

YTD Revenues: $19.3 billion (+3%)

YTD Earnings: $3.0 billion (+6%)

Comments: Proprietary Pharmaceutical sales were $8.5 billion (+1%) in the quarter. Established Pharmaceutical sales were $2.5 billion (-6%). Humira sales were up 8% to $2.3 billion in the quarter. TRILIPIX/TriCor sales were down 12% to $388 million. AndroGel sales were down 10% to $284 million. Kaletra sales dropped 20% to $275 million. Lupron sales were down 14% to $200 million. Nutritionals business grew 6% to $1.6 billion driven by U.S. sales up 13% to $741 million. Results include a 4.7% unfavorable impact from foreign exchange.